cyrilzakka/clinical-trials huggingface dataset:
fNIRS-Based Neurofeedback Training in Children With ADHD: The Effects of VR

The study aims to explore whether the treatment using fNIRS-based neurofeedback training for children with attention-deficit/hyperactivity disorder (ADHD) is useful. Furthermore, the study hopes to evaluate whether the use of virtual reality (VR) technology will have an impact on the treatment's effectiveness.

The program includes the following components:

Participants will be randomly assigned to one of three intervention groups: the neurofeedback with virtual reality (VR) group, the 2D neurofeedback group (with no VR technology applied), and the VR without neurofeedback group. All participants will complete academic-related tasks in simulated lessons. Participants in the VR neurofeedback group will wear VR goggles and a neurofeedback device that measures blood oxy-hemoglobin levels in brain cortical tissue and provides feedback via visual images or auditory sounds to the participants. Those in the 2D neurofeedback group will use a computer to complete the tasks, with all other settings (e.g., neurofeedback settings) remaining the same. The VR without neurofeedback group will wear VR goggles to complete tasks, but without the neurofeedback component.

All participants will complete a total of 16 training sessions over 8 weeks (twice a week), with each session lasting approximately 35 to 60 minutes.

To investigate the intervention's effectiveness, children will be asked to complete a set of cognitive tests covering inhibitory control, attention, and working memory before the intervention (i.e., Time 1), immediately after the 8-week training (i.e., Time 2), and 2 months after the training (i.e., Time 3, a 2-month follow-up). The assessment will take around 1 hour and will be conducted at the laboratory at the University of Hong Kong. Additionally, parents and teachers will be asked to complete a questionnaire assessing children's behavior at home and at school at three time points.


Eligibility Criteria:
Inclusion Criteria:

* Children aged 7- 12
* Clinical diagnosis of ADHD
* Significant teacher- or parent-reported attention problems during screening

Exclusion Criteria:

* Inability to answer the first five questions in Raven's Progressive Matrices
* Hearing, visual, or physical impairments that might hinder participation in the training and assessment activities
* Clinical diagnosis and suspected cases of Autism Spectrum Disorder (ASD)
* Prior or current participation in NFT
* Current participation in a psychotherapeutic treatment
REcommened Communication With Sympathy in Terminally Ill Cancer Patients Treated With Palliative Sedation

* In terminally ill cancer patients, palliative sedation has been applied to intractable refractory symptoms such as pain, dyspnea, delirium, agitation.
* Palliative sedation is generally an adaptive strategies using midazolam, which is composed of intermittent bolus, limited continuous, or 24hr continuous infusion depending on the time of drug application.
* In the application of palliative sedation, caregiver's negative feelings such as anxiety or guilt for palliative sufficiency are one of the biggest challenges as the patient's consciousness is reduced, and they feels disconnected from the patient.
* In general, hearing is known to persist until the very last moment of the end of life, regardless of consciousness. In addition, maintaining communication with patients and caregivers is the most important part of the hospice.
* This study evaluate the efficacy of healthcare provider's recommended communication with sympathy, "Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end."


Eligibility Criteria:
Inclusion Criteria:

* Patients who are expected to die within a few weeks due to disease progression without additional anti-tumor treatment plans.
* Patients who are the target of palliative sedation because intractable symptom such as pain, dyspnea, delirium, or agitation persist as even after the conservative treatment.
* Patients who have agreed to palliative sedation.

Exclusion Criteria:

* Patients treated with a palliative sedation methods using bolus application or other drugs (lorazepam, etc.) rather than continuous midazolam were excluded.
* In case of the guardian is unable to stay with the patient for more than 6 hours per day, the patients were excluded.
Effect of Brief Mindfulness and Relaxation Inductions on Anxiety, Affect and Brain Activation in Athletes

The athlete population has a high risk of suffering from mental health problems (e.g., anxiety), especially for athletes with individual sports. As such, various forms of mental training were used to maintain the mental health of athletes, such as mindfulness training or relaxation training. However, differences pertaining to the electrophysiological mechanisms resulting from both mental training in athletes are unknown. Therefore, the purpose of the current study was to examine the differential effects between the brief mindfulness induction (MI) and relaxation induction (RI) on state anxiety, affect and the activation of the brain in track and field athletes.

The purposes of this study are: (1) examining the effect of brief mindfulness induction (MI) and relaxation induction (RI) on anxiety and affect in athletes with individual sports, (2) and we sought to identify the different brain activity (i.e., theta, alpha) changes between MI and RI using EEG. In the present study, subjects were contrasted using a within-subject comparison across MI, RI, and control condition. According to past works on the comparison of mindfulness and psychological skill training, we hypothesized that MI and RI would both improve anxiety and affect, compared with control condition. Furthermore, we also hypothesized that RI would elicit greater theta power (i.e., more cognitive control) than MI. In addition, when compared with control condition, participants might be elicited greater alpha power during the MI and RI.

Eligibility Criteria:
Inclusion Criteria:

1. track and field athletes with regular training
2. right-handedness
3. no history of neurological illness
4. no regular training experience in mindfulness or relaxation interventions

Exclusion Criteria:

-
A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. The patient population will consist of hospitalized, medically ill (non-surgical, non-obstetrical) individuals aged \> 60 years.

Investigators, plan to do a study using a pragmatic, randomized design as part of a Quality Improvement (QI) project as a substudy within the existing NIH R18 proposal of creating a universal "SMART on FHIR" platform of the IMPROVE VTE CPR for key Northwell Health hospitals. Investigators, aim is to assess whether an EHR-embedded CPR for VTE prevention - the IMPROVE VTE CPR - ultimately tied to electronic order entry will increase the proportion of hospitalized medical patients at risk of VTE who receive appropriate thromboprophylaxis, both at hospital admission AND at hospital discharge, compared to UMC. Investigators, secondary aims are to assess whether key adverse outcomes such as symptomatic VTE and hospital readmission for VTE are reduced and whether health -resource utilization metrics are improved.

Eligibility Criteria:
Inclusion Criteria:

• Patients with an acute medical illness and ONE of the following risk factors:

* Age \> 60 years
* Presence of known thrombophilia
* Intensive care unit (ICU)/coronary care unit (CCU) stay
* Lower extremity paralysis
* Cancer
* Immobilization
* Previous VTE history
* D-dimer (\>2X ULN)

Exclusion Criteria:

• Patients with the following factors:

* Therapeutic anticoagulation
* History of recent bleeding.
* Active gastroduodenal ulcer
* Thrombocytopenia (admission platelet count\< 75x 109 cells/L )
* Coagulopathy (baseline INR \> 1.5)
* Severe renal insufficiency (baseline)CrCl \< 30ml/min)
* Dual antiplatelet therapy
* Bronchiectasis/pulmonary cavitation
* Active cancer, and recent major surgery within 30 days of their index hospitalization bleeding.
Lamictal Bipolar Observational Study

This is multi-center, prospective, observational stud. This study is designed to evaluate the rate of non-serious rash in Korean bipolar I patients.


Eligibility Criteria:
Inclusion criteria:

* A subject will be eligible for inclusion in this study only if all of the following criteria apply:
* Provides written informed consent
* Male or female age 18 years or older A female subject is eligible to enter and participate in the study if she is of;
* Non-childbearing potential
* Childbearing potential, has a negative pregnancy test at screen
* Diagnosis of bipolar I disorder using DSM-IV criteria

Exclusion criteria:

* A subject will not be eligible for inclusion in this study if any of the following criteria apply:
* Previous or current treatment with lamotrigine
* Presence of a clinically significant psychiatric or physiologic comorbidity, including significant substance abuse, severe depression or mania which is of an unstable or progressive nature that could, in the opinion of the investigator, interfere with participation in this study
* Presence of untreated thyroid disease
* Have active suicidality or homicidality, history of recent suicide attempts within the past year, or, in the investigator's opinion, a marked risk for suicide
* History of severe hepatic or renal insufficiency or significant hematologic disease or other significant medical or psychiatric condition that would interfere with subjects' participation in the study
* Currently participating in another clinical trial, or plans to enroll in another trial while participating in this study
* Currently pregnant or is breastfeeding
HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix

High-risk type human papillomavirus (HPV) is the known etiological agent of cervical cancer. HPV testing and risk stratification by genotyping has been recognized as an effective cervical screening program. A chip for HPV DNA typing based on type-specific polymerase chain reaction (PCR), DR. HPV Genotyping IVD Kit (HPV-27) was developed for genotyping of 27 common HPV types including all high-risk types. We studied its agreement, sensitivity, and specificity compared to DNA sequencing as the gold standard.

High-risk type human papillomavirus (HPV) is the known etiological agent of cervical cancer. HPV testing and risk stratification by genotyping has been recognized as an effective cervical screening program. HPV detection is also applied for triage of atypical squamous cells of undetermined significance and follow-up after treatment for cervical neoplasms. A chip for HPV DNA typing based on type-specific polymerase chain reaction (PCR), DR. HPV Genotyping IVD Kit (HPV-27) was developed for genotyping of 27 common HPV types including all high-risk types. We studied its agreement, sensitivity, and specificity compared to DNA sequencing as the gold standard.

One-thousand one-hundred and three (1103) subjects were enrolled between December 2012 and December 2013 from Linkou Chang Gung Memorial Hospital, Mackay Memorial Hospital, Changhua Christian Hospital, and Cathay General Hospital.

Eligibility Criteria:
Inclusion Criteria:

1. 21-65 y/o female with sexual exposure
2. Written informed consent
3. Either one of the following conditions:

3a. No previous history of abnormal cervical cytology or abnormal histology for women enrolled in no intraepithelial lesion or malignancy (NILM) group 3b. Abnormal cervical cytology other than atrophic change, reactive change or glandular cells favored of the endometrial origin

Exclusion Criteria:

1. Current pregnancy
2. Previous total hysterectomy
3. Cervicovaginal infection required treatment
4. Received cervical ablative therapy within 1 year
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors

The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients' own feelings about their survival

Patients with incurable cancer frequently ask their doctors for an estimate of survival. Such estimates can assist patients in making decisions about how best to spend their time and energy. Survival estimates are also required when considering patients with incurable cancer for experimental treatments. However, such estimates are difficult to make. There is some data to suggest that a simple clinical measure, the performance status, combined with a laboratory blood test, the LDH, may assist in making the survival estimate more realistic. This study is designed to test if this is the case, using patients with metastatic lung, breast, colorectal, prostate, or pancreatic cancer or patients with cancer of unknown primary who have exhausted life-prolonging therapy. These patients will be asked to consent to entering this study. Their performance status will be assessed by the Karnofsky and WHO scales, they will be asked to have their blood tested for LDH and they and their doctor will be asked to estimate their survival. After study entry they will be allowed to receive palliative radiotherapy, surgery or systemic therapy as indicated including protocol treatment. After study entry, the only other requirement is that the date of the patients death be reported so that the duration of survival can be compared with the doctors and patients estimate and correlated with the performance status and LDH.

Eligibility Criteria:
Inclusion Criteria:

1. All patients must be at least 18 years of age
2. All patients must have documented incurable metastatic cancer
3. All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible:

   1. Non-small cell lung cancer patients after third systemic therapy
   2. Small cell lung cancer patients after second systemic therapy
   3. Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy)
   4. Colorectal cancer patients after second systemic therapy
   5. Hormone refractory prostate cancer patients after first cytotoxic therapy
   6. Cancer of unknown primary
   7. Pancreatic cancer patients after first systemic therapy
4. The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed
5. Patients with a history of previous cancers are allowed
6. Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed
7. All patients must sign informed consent

Exclusion Criteria:

1. Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded
2. Patients who do not sign informed consent are excluded
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting

This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled in the CorEvitas RA Registry and initiated tofacitinib on or after November 2012.
* Initiate tofacitinib (defined as first ever use of tofacitinib) at Registry enrollment visit or at a Registry follow-up visit after November 2012
* Have prior use of rituximab
* Have CDAI measured at baseline and appropriate follow-up visit.

Exclusion Criteria:

* There are no exclusion criteria for this study
Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices

The main complications of cirrhosis are ascites, esophageal varices and hepatic encephalopathy. About 30% to 70% patients with cirrhosis occur esophageal varices, and the most common complication is ascites. Somatostatin is used to treat esophageal for a long time, otherwise it could aslo prevent ascites. In the study, the investigators explore the effects of somatostatin on post-endoscopic portal hemodynamic in cirrhotic patients with esophageal gastric varices.

126 patients will be enrolled in the study, 63 subjects will be randomized into the group A and the other will be into the group B.

Group A: endoscopic therapy and somatostatin treatment. Group B: endoscopic therapy.

Eligibility Criteria:
Inclusion Criteria:

* Cirrhosis with esophageal gastric varices needed endoscopic therapy
* Age 18-75 years
* Informed written consent

Exclusion Criteria:

* Use of vasoactive drugs 24 hours before endoscopic treatment
* Use of B-blocker within 1 week
* Previous surgical or endoscopic treatment for esophageal gastric varices
* Hepatic encephalopathy,comatose status and any other disease which could not accept endoscopic therapy
* Gastro-renal vein shunt
* Severe hepatic hydrothorax
* Hepatocellular carcinoma with portal vein thrombosis
* Severe coagulation disorders
* Severe active bacteria infection
* Severe cardiovascular disease, including a history of acute myocardial infarction,heart block, heart failure
* Severe renal function insufficiency （Calculated Creatinine Clearance Rate (Ccr) \<30ml/min）
* Severe co-morbidity that would affect short-term prognosis
* Pregnancy or lactation
* Allergy to any ingredient of trial medication
* Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin

This is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor.

Atopic dermatitis, also known as eczema, is a long-lasting skin disease that causes redness, swelling, dryness, cracking, and intense itching. Xerosis is the scientific wording to describe dry skin. This condition is caused by a weakened skin barrier that does not hold moisture well.

DIPROBASE® advanced eczema cream is already available for use in the UK. It moisturizes and protects the skin.

This study is being done to understand how people use DIPROBASE® Advanced Eczema Cream and how consistently they adhere to its recommended use in their daily routines. In this study, participants will be asked to fill in an online questionnaire about their eczema symptoms and experience with DIPROBASE® Advanced Eczema Cream.

No treatment advice will be given as a part of this study.

The main purpose of this study is to gather feedback from people in the UK who have used DIPROBASE® Advanced Eczema Cream to treat their eczema or their dry skin condition. To do this, researchers will collect the following information from participants:

* intensity of eczema symptoms
* whether the cream provides a cooling or soothing effect
* whether the cream helps to ease the symptoms like itchiness, pain, or dryness

It is planned to identify and collect user data from November 2024 to January 2025. Participants will be recruited through a consumer database available with an external partner or via social media.

In this study, only data are collected. No visits or tests are required as part of this study.


Eligibility Criteria:
Inclusion Criteria:

Participants:

* Biological sex: M/F.
* Age: \> or equal to 18 years of age.
* Mothers, fathers, grandparents, and other caregivers aged 18 years of age and above, who will report data on themselves, their children from 2 to 12 years of age or their infants under 2 years of age.
* Able to read and understand the language of the online questionnaire.
* Have used the product within the previous three (3) months.
* Agree that the data collected can be used for research, marketing and regulatory purposes.

Exclusion Criteria:

* Due to the real-world nature of the study, there are no exclusion criteria.
Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

evaluate the safety and efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in treatment of chinese patients with acne.


Eligibility Criteria:
Inclusion Criteria:

1. Age from 18 to 40 years old, female or male;
2. Class I-III of Acne vulgaris according to the International Modified PILLSBURY Classification;
3. Patients voluntarily take part in the study and sign the ICF.

Exclusion Criteria:

1. The subject is known to be allergic to adapalene, clindamycin hydrochloride, clindamycin, and / or any components of gel excipient;
2. Patients with secondary acne including occupational acne and corticosteroid-induced acne;
3. The affected skin has other concomitant lesion (such as solar dermatitis, psoriasis, seborrheic dermatitis, eczema and extremely severe acne) which may impact the efficacy evaluation;
4. Subject has the history of regional enteritis, ulcerative colitis or antibiotic-associated colitis;
5. Patient has history of severe cardiac disease and hypertension;
6. Patient has severe liver and kidney diseases with AST/ALT more than twice upper limitation, or Cr, total cholesterol and triglycerides above normal range;
7. Patients with severe endocrine diseases, blood diseases, and neuropsychiatric disorders;
8. Patients are known to have severe immune dysfunction, or need long-term use of corticosteroids or immunosuppressive agents;
9. Pregnant or breastfeeding women, or unwilling to take effective contraceptive measures during the study;
10. Alcoholic patients or drug abusers;
11. Patient has used other acne drugs topically within 2 weeks before the study start;
12. Patient has been administered with victoria A acid, vitamins, and antibiotics within 4 weeks before the study start;
13. Patient has participated in other study within 3 months before the study start;
14. The subject is not fit to take part in this study in the judgment of the investigator.